AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.Tokyo, Japan, June 7, 2006 - (JCN) - AnGes MG announced on June 5 its future strategies for the development of AMG0001, HGF HGF, n See glucagon. (Hepatocyte Growth Factor Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. ) gene medicine. Specifically, the company will reinforce its current partnership with Daiichi Pharmaceutical. Further, AnGes MG has decided to place the highest priority on development in the field of peripheral arterial disease in Japan. Regarding overseas development, AnGes MG will proceed with research in both peripheral arterial disease (PAD) and ischemic heart disease Ischemic heart disease Insufficient blood supply to the heart muscle (myocardium). Mentioned in: Myocarditis ischemic heart disease (IHD IHD ischemic heart disease. ). Currently, AnGes MG and Daiichi Pharmaceutical are jointly undertaking phase II and III clinical trials for PAD overseas and in Japan, respectively, and phase I and pre-clinical trials for IHD overseas and in Japan, respectively. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion